Pharming Group Secures EU Approval for Joenja Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2026
0mins
Source: NASDAQ.COM
- Drug Approval: Pharming Group's Joenja (leniolisib) has received marketing authorization from the European Commission, becoming the first and only approved treatment for activated PI3K delta syndrome (APDS) in patients aged 12 and older, marking a significant advancement in the rare immunodeficiency space.
- Market Launch Plans: Joenja is expected to launch in Germany in Q3 2026, with additional launches contingent on national reimbursement negotiations, laying the groundwork for the company's expansion in the European market.
- Regulatory Review Progress: Leniolisib is currently under regulatory review in Canada and several other countries, indicating its global market potential, while also being evaluated in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation, further broadening its indications.
- Stock Price Fluctuation: Pharming's stock closed at $12.60 on May 22, down 1.64%, but rebounded to $13.03 in after-hours trading, gaining 3.41%, reflecting positive market sentiment following the drug approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.660
Low
37.00
Averages
39.50
High
42.00
Current: 13.660
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharming Group Secures EU Approval for Joenja Treatment
- Drug Approval: Pharming Group's Joenja (leniolisib) has received marketing authorization from the European Commission, becoming the first and only approved treatment for activated PI3K delta syndrome (APDS) in patients aged 12 and older, marking a significant advancement in the rare immunodeficiency space.
- Market Launch Plans: Joenja is expected to launch in Germany in Q3 2026, with additional launches contingent on national reimbursement negotiations, laying the groundwork for the company's expansion in the European market.
- Regulatory Review Progress: Leniolisib is currently under regulatory review in Canada and several other countries, indicating its global market potential, while also being evaluated in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation, further broadening its indications.
- Stock Price Fluctuation: Pharming's stock closed at $12.60 on May 22, down 1.64%, but rebounded to $13.03 in after-hours trading, gaining 3.41%, reflecting positive market sentiment following the drug approval.
See More
Pharming Group Receives EU Marketing Authorization
- Marketing Authorization Granted: Pharming Group announced late Friday that the European Commission has granted marketing authorization for its product, marking a significant step in the company's expansion into the European market, which is expected to positively impact sales growth.
- Product Potential Unleashed: With the marketing authorization, Pharming's product will be able to be sold across the EU, enhancing the company's competitive position and potentially attracting more investor interest in its future developments.
- Strategic Positioning Enhanced: The authorization allows Pharming to more effectively penetrate the European market, leveraging local sales networks and resources to strengthen its market position in the biopharmaceutical industry.
- Future Growth Expectations: With the implementation of the marketing authorization, Pharming anticipates revenue growth, further advancing its strategic goals in the global biopharmaceutical sector, particularly in meeting patient needs.
See More
Joenja® Approved in EU for APDS Treatment
- First Approved Treatment: Joenja® (leniolisib) is the first approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the European Union, applicable to adults and pediatric patients aged 12 and older, marking a significant advancement in the rare immunodeficiency field.
- Launch in Germany: The first European launch of Joenja® is expected in Germany in Q3 2026, with additional launches anticipated based on the completion of national reimbursement negotiations, demonstrating the company's strategic commitment to global market expansion.
- Clinical Trial Support: The approval is based on a multinational, triple-blind, placebo-controlled Phase II/III clinical trial that showed statistically significant improvements in immune dysregulation and immunodeficiency markers in 31 patients, indicating its efficacy in treating APDS.
- Long-term Safety Data: The application included long-term open-label extension data from 37 patients, demonstrating good safety and tolerability over a median of three years of use, further enhancing its prospects in rare disease treatment.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting
- Presentation Schedule: Pharming Group N.V. will deliver multiple scientific presentations at the Clinical Immunology Society Annual Meeting from May 6-9, 2026, in New Orleans, showcasing new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
- Focus on Pediatric Study: One presentation will concentrate on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand treatment access beyond the currently approved age group.
- Clinical Experience Data: Additional presentations will describe real-world and clinical experience data in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders, findings from the APDS-CHOIR registry, and caregiver and clinician-reported symptom assessments in pediatric APDS.
- Ongoing Study Design: Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.
See More
Pharming Presents Research Findings at CIS Annual Meeting
- Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
- Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
- Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
- Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.
See More
Pharming Group Secures EU Approval for Joenja Treatment
- Drug Approval: Pharming Group's Joenja (leniolisib) has received marketing authorization from the European Commission, becoming the first and only approved treatment for activated PI3K delta syndrome (APDS) in patients aged 12 and older, marking a significant advancement in the rare immunodeficiency space.
- Market Launch Plans: Joenja is expected to launch in Germany in Q3 2026, with additional launches contingent on national reimbursement negotiations, laying the groundwork for the company's expansion in the European market.
- Regulatory Review Progress: Leniolisib is currently under regulatory review in Canada and several other countries, indicating its global market potential, while also being evaluated in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation, further broadening its indications.
- Stock Price Fluctuation: Pharming's stock closed at $12.60 on May 22, down 1.64%, but rebounded to $13.03 in after-hours trading, gaining 3.41%, reflecting positive market sentiment following the drug approval.
See More
Pharming Group Receives EU Marketing Authorization
- Marketing Authorization Granted: Pharming Group announced late Friday that the European Commission has granted marketing authorization for its product, marking a significant step in the company's expansion into the European market, which is expected to positively impact sales growth.
- Product Potential Unleashed: With the marketing authorization, Pharming's product will be able to be sold across the EU, enhancing the company's competitive position and potentially attracting more investor interest in its future developments.
- Strategic Positioning Enhanced: The authorization allows Pharming to more effectively penetrate the European market, leveraging local sales networks and resources to strengthen its market position in the biopharmaceutical industry.
- Future Growth Expectations: With the implementation of the marketing authorization, Pharming anticipates revenue growth, further advancing its strategic goals in the global biopharmaceutical sector, particularly in meeting patient needs.
See More
Joenja® Approved in EU for APDS Treatment
- First Approved Treatment: Joenja® (leniolisib) is the first approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the European Union, applicable to adults and pediatric patients aged 12 and older, marking a significant advancement in the rare immunodeficiency field.
- Launch in Germany: The first European launch of Joenja® is expected in Germany in Q3 2026, with additional launches anticipated based on the completion of national reimbursement negotiations, demonstrating the company's strategic commitment to global market expansion.
- Clinical Trial Support: The approval is based on a multinational, triple-blind, placebo-controlled Phase II/III clinical trial that showed statistically significant improvements in immune dysregulation and immunodeficiency markers in 31 patients, indicating its efficacy in treating APDS.
- Long-term Safety Data: The application included long-term open-label extension data from 37 patients, demonstrating good safety and tolerability over a median of three years of use, further enhancing its prospects in rare disease treatment.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting
- Presentation Schedule: Pharming Group N.V. will deliver multiple scientific presentations at the Clinical Immunology Society Annual Meeting from May 6-9, 2026, in New Orleans, showcasing new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
- Focus on Pediatric Study: One presentation will concentrate on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand treatment access beyond the currently approved age group.
- Clinical Experience Data: Additional presentations will describe real-world and clinical experience data in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders, findings from the APDS-CHOIR registry, and caregiver and clinician-reported symptom assessments in pediatric APDS.
- Ongoing Study Design: Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.
See More
Pharming Presents Research Findings at CIS Annual Meeting
- Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
- Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
- Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
- Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.
See More
